BeiGene tops other pharmaceutical companies over Q2 2023. Credit: Shutterstock via Lemonsoup14

Each week, Clinical Trials Arena journalists pick out insights from company filings that highlight sentiments in our sector. These filings signals are based on GlobalData’s analysis of earnings statements, call transcripts, investor presentations and sustainability reports. They tell us about key topics on the minds of business leaders and investors, and the themes driving a company’s activities.  

This new, thematic filings coverage is powered by our underlying Disruptor data which tracks all major deals, patents, company filings, hiring patterns and social media buzz across our sectors.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

This week, we consider the pharmaceutical industry’s top gainers and losers from quarterly filings over Q2 2023. According to GlobalData reports, BeiGene was at the top for gainers in that quarter clinching high financial percentage growths, followed by Mercury Laboratories, Voya Therapeutics and Navibra Therapeutics.

Meanwhile, the same could not be said for Gujarat Terce Laboratories, Syngene International, Shree Ganesh Remedies International, and Aurobindo Pharma as they turned up with a low percentage increase in their financial results; hence, top losers over the second quarter.

See Also:

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Hitting rock bottom for top gainers are the following pharmaceutical companies: Gelesis Holdings, Aarti Drugs, Ayala Pharmaceuticals, Angion Biomedica. However, Eupraxia Pharmaceuticals, Disc Medicine, Noxopharm, and Timber Pharmaceuticals had low financial results for the second quarter of 2023, sitting at the bottom of the reported top losers.

GlobalData is the parent company of Clinical Trials Arena.